AMAG Pharmaceuticals
As of the edition of 20 October 2026, AMAG Pharmaceuticals runs 5 drugs, 4 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- Lumara Health, Inc.: acquired in 2014; successor AMAG Pharmaceuticals, Inc.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Stopped | 1 |
| Total | 5 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Ferumoxytol | Ends 2028 (exclusivity) | 0 |
| Bremelanotide | none listed | 0 |
| Ferumoxides | none listed | 0 |
| Ferumoxsil | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Blood and lymph: 13 trials led
- Nutrition and metabolism: 11 trials led
- Pregnancy and women's health: 4 trials led